Capstone Therapeutics Corp. (NASDAQ:CAPS) Sees Large Decrease in Short Interest

Capstone Therapeutics Corp. (NASDAQ:CAPS) was the recipient of a large decrease in short interest in December. As of December 31st, there was short interest totaling 54,947 shares, a decrease of 74.3% from the December 15th total of 213,740 shares. Based on an average daily volume of 162,551 shares, the short-interest ratio is presently 0.3 days. Approximately 1.6% of the company’s stock are short sold. Approximately 1.6% of the company’s stock are short sold. Based on an average daily volume of 162,551 shares, the short-interest ratio is presently 0.3 days.

Hedge Funds Weigh In On Capstone Therapeutics

An institutional investor recently bought a new position in Capstone Therapeutics stock. World Investment Advisors purchased a new position in Capstone Therapeutics Corp. (NASDAQ:CAPS) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 29,000 shares of the company’s stock, valued at approximately $38,000. World Investment Advisors owned about 0.40% of Capstone Therapeutics at the end of the most recent quarter. Institutional investors own 2.55% of the company’s stock.

Capstone Therapeutics Stock Performance

Capstone Therapeutics stock opened at $0.62 on Thursday. Capstone Therapeutics has a 12-month low of $0.60 and a 12-month high of $4.18. The company has a debt-to-equity ratio of 0.29, a current ratio of 0.95 and a quick ratio of 0.35. The company has a market capitalization of $5.17 million, a price-to-earnings ratio of -0.66 and a beta of -1.21. The firm’s fifty day moving average price is $0.82 and its 200 day moving average price is $1.14.

Capstone Therapeutics (NASDAQ:CAPS) last announced its earnings results on Tuesday, November 18th. The company reported ($0.35) earnings per share for the quarter. Capstone Therapeutics had a negative net margin of 12.40% and a negative return on equity of 29.50%. The business had revenue of $13.65 million for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Capstone Therapeutics in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Capstone Therapeutics presently has an average rating of “Sell”.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.